Current treatments and emerging therapies of human polyomavirus-associated skin diseases : a comprehensive review
© 2022 the International Society of Dermatology..
Since Merkel cell polyomavirus (MCPyV) was linked as the predominant etiology of Merkel cell carcinoma (MCC) in 2008, three additional human polyomaviruses (HPyV) have been definitively linked to cutaneous diseases-trichodysplasia spinulosa virus (TSPyV) and human polyomavirus 6 and 7 (HPyV6, HPyV7). TSPyV contributes to the development of trichodysplasia spinulosa (TS), and HPyV6/7 is associated closely with the eruption of pruritic and dyskeratotic dermatoses (PDD). Clinically, MCC is treated with surgical excision and radiation with adjuvant chemotherapy, although newer treatment options include immune checkpoint inhibition. These novel immunotherapies hold promise for the treatment of metastatic MCC, but resistance and side effects prevent a significant proportion of patients from realizing their benefits. Based on previous case reports, the standard of care for the less deadly but disfiguring cutaneous disease TS include immunosuppressant (IS) reduction, the use of antivirals such as cidofovir (CDV) or valganciclovir (VGCV), or a combination of these treatments. Similar treatments were attempted for PDD, but oral acitretin was found to be most effective. As MCC, TS, and PDD are rare diseases, further research is required for effective treatments. In this review, we summarize clinical trials, preclinical studies, and case reports that present outcomes and side effects of current and emerging treatments for HPyV-associated cutaneous diseases, offering a comprehensive resource for clinical application and prospective clinical trials.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
---|---|
Enthalten in: |
International journal of dermatology - 62(2023), 3 vom: 17. März, Seite 387-396 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Bartley, Brooke R [VerfasserIn] |
---|
Links: |
---|
Themen: |
---|
Anmerkungen: |
Date Completed 24.02.2023 Date Revised 24.02.2023 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1111/ijd.16534 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM350891273 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM350891273 | ||
003 | DE-627 | ||
005 | 20231226050023.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1111/ijd.16534 |2 doi | |
028 | 5 | 2 | |a pubmed24n1169.xml |
035 | |a (DE-627)NLM350891273 | ||
035 | |a (NLM)36577746 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Bartley, Brooke R |e verfasserin |4 aut | |
245 | 1 | 0 | |a Current treatments and emerging therapies of human polyomavirus-associated skin diseases |b a comprehensive review |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 24.02.2023 | ||
500 | |a Date Revised 24.02.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2022 the International Society of Dermatology. | ||
520 | |a Since Merkel cell polyomavirus (MCPyV) was linked as the predominant etiology of Merkel cell carcinoma (MCC) in 2008, three additional human polyomaviruses (HPyV) have been definitively linked to cutaneous diseases-trichodysplasia spinulosa virus (TSPyV) and human polyomavirus 6 and 7 (HPyV6, HPyV7). TSPyV contributes to the development of trichodysplasia spinulosa (TS), and HPyV6/7 is associated closely with the eruption of pruritic and dyskeratotic dermatoses (PDD). Clinically, MCC is treated with surgical excision and radiation with adjuvant chemotherapy, although newer treatment options include immune checkpoint inhibition. These novel immunotherapies hold promise for the treatment of metastatic MCC, but resistance and side effects prevent a significant proportion of patients from realizing their benefits. Based on previous case reports, the standard of care for the less deadly but disfiguring cutaneous disease TS include immunosuppressant (IS) reduction, the use of antivirals such as cidofovir (CDV) or valganciclovir (VGCV), or a combination of these treatments. Similar treatments were attempted for PDD, but oral acitretin was found to be most effective. As MCC, TS, and PDD are rare diseases, further research is required for effective treatments. In this review, we summarize clinical trials, preclinical studies, and case reports that present outcomes and side effects of current and emerging treatments for HPyV-associated cutaneous diseases, offering a comprehensive resource for clinical application and prospective clinical trials | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
700 | 1 | |a Moore, Stephen A |e verfasserin |4 aut | |
700 | 1 | |a Doan, Hung Q |e verfasserin |4 aut | |
700 | 1 | |a Rady, Peter L |e verfasserin |4 aut | |
700 | 1 | |a Tyring, Stephen K |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t International journal of dermatology |d 1970 |g 62(2023), 3 vom: 17. März, Seite 387-396 |w (DE-627)NLM000017515 |x 1365-4632 |7 nnns |
773 | 1 | 8 | |g volume:62 |g year:2023 |g number:3 |g day:17 |g month:03 |g pages:387-396 |
856 | 4 | 0 | |u http://dx.doi.org/10.1111/ijd.16534 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 62 |j 2023 |e 3 |b 17 |c 03 |h 387-396 |